Company Overview and News

0
Promoters forgo salary for second straight year as Hotel Leela#39;s financial mess worsens

2018-08-14 moneycontrol
The chairman and co-chairman of Hotel Leelaventure were forced to forgo their full salaries for the financial year ended March as the company continued to grapple with a huge pile of debt on its books.
500193 HOTELEELA

0
Hotel Leelaventure defaults on payment of quarterly interest to Life Insurance Corporation of India

2018-06-22 moneycontrol
Cash-strapped hospitality chain Hotel Leela Venture has defaulted in payment of quarterly interest of Rs 2.12 crore to Life Insurance Corporation of India (LIC).
500193 HOTELEELA

0
Hotel Leela board to consider 125 cr share issue to JM Financial

2018-06-04 moneycontrol
Hotel Leela Venture today said its board will meet on June 11 to approve a share issue of up to 125 crore shares on preferential basis to JM Financial Asset Reconstruction Company for converting of part of debt into equity.
523405 500193 HOTELEELA JMFINANCIL

0
Hotel Leelaventure defaults on NCD interest to LIC

2018-04-17 thehindubusinessline
Our Bureau Hotel Leelaventure on Tuesday said that it has defaulted on interest and principal payments since 2016, on the ₹90-crore non-convertible debentures issued to Life Insurance Corporation of India.
500193 HOTELEELA 500696 HINDUNILVR

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...